<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="monograph-family" /><meta name="keywords" content="Amiodarone; Beta-adrenoceptor blocking drugs: arrhythmias; Disopyramide; Flecainide; Propafenone; Mexiletine; Procainamide" /><meta name="IX" content="Amiodarone; Beta-adrenoceptor blocking drugs: arrhythmias; Disopyramide; Flecainide; Propafenone; Mexiletine; Procainamide" /><title>Supraventricular and ventricular arrhythmias: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="2416.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="2416.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=2416.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="1002.htm">2 Cardiovascular system</a> &gt; <a href="2408.htm">2.3 Anti-arrhythmic drugs</a> &gt; <a href="2410.htm">2.3.2 Drugs for arrhythmias</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="206568.htm" title="Previous: DRONEDARONE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="2417.htm" title="Next: AMIODARONE HYDROCHLORIDE">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_2416">Supraventricular and ventricular arrhythmias</h1><?highlighter on?><div id="pC" class="jN"><div class="cAJ"><span class="cAD">Additional information</span> interactions (<a href="41001i118.htm" title="Go to appendix 1">Amiodarone</a>).</div><div><p><b>Amiodarone </b>is used in the treatment of arrhythmias,
particularly when other drugs are ineffective or contra-indicated.
It can be used for paroxysmal supraventricular, nodal and ventricular
tachycardias, atrial fibrillation and flutter, and ventricular fibrillation.
It can also be used for tachyarrhythmias associated with Wolff-Parkinson-White
syndrome. It should be initiated only under hospital or specialist
supervision. Amiodarone may be given by intravenous infusion as well
as by mouth, and has the advantage of causing little or no myocardial
depression. Unlike oral amiodarone, intravenous amiodarone acts relatively
rapidly.</p><p>Intravenous injection of amiodarone can be used in cardiopulmonary
resuscitation for ventricular fibrillation or pulseless tachycardia
unresponsive to other interventions (section 2.7.3).</p><p>Amiodarone has a very long half-life (extending to several weeks)
and only needs to be given once daily (but high doses can cause nausea
unless divided). Many weeks or months may be required to achieve steady-state
plasma-amiodarone concentration; this is particularly important when
drug interactions are likely (see also Appendix 1).</p><p>Most patients taking amiodarone develop corneal microdeposits
(reversible on withdrawal of treatment); these rarely interfere with
vision, but drivers may be dazzled by headlights at night. However,
if vision is impaired or if optic neuritis or optic neuropathy occur,
amiodarone must be stopped to prevent blindness and expert advice
sought. Because of the possibility of phototoxic reactions, patients should be advised to shield the skin from light during treatment
and for several months after discontinuing amiodarone; a wide-spectrum sunscreen (<a title=" Sunscreening preparations" href="6075.htm#_6075">section 13.8.1</a>) to protect against both long-wave
ultraviolet and visible light should be used.</p><div id="_2416.2"><p>Amiodarone
contains iodine and can cause disorders of thyroid function; both
hypothyroidism and hyperthyroidism may occur. Clinical assessment
alone is unreliable, and laboratory tests should be performed before
treatment and every 6 months. Thyroxine (T4) may be raised in the
absence of hyperthyroidism; therefore tri-iodothyronine (T3), T4,
and thyroid-stimulating hormone (thyrotrophin, TSH) should all be
measured. A raised T3 and T4 with a very low or undetectable TSH concentration
suggests the development of thyrotoxicosis. The thyrotoxicosis may
be very refractory, and amiodarone should usually be withdrawn at
least temporarily to help achieve control; treatment with <span>carbimazole</span> may be required. Hypothyroidism can be treated
with replacement therapy without withdrawing amiodarone if it is essential;
careful supervision is required.</p></div><p>Pneumonitis should always be suspected if new
or progressive shortness of breath or cough develops in a patient
taking amiodarone. Fresh neurological symptoms should raise the possibility
of peripheral neuropathy. </p><p>Amiodarone is also associated with hepatotoxicity
and treatment should be discontinued if severe liver function abnormalities
or clinical signs of liver disease develop.</p><p><b>Beta-blockers</b> act as anti-arrhythmic drugs principally
by attenuating the effects of the sympathetic system on automaticity
and conductivity within the heart, for details see <a title=" Beta-adrenoceptor blocking drugs" href="2455.htm#_2455">section 2.4</a>. For special reference to the role
of <b>sotalol</b> in ventricular arrhythmias, see  <a title="target-block: sotalol in ventricular arrhythmias" href="2455.htm#_120503">Arrhythmias</a>.</p><p><b>Disopyramide</b> can be given by intravenous injection
to control arrhythmias after myocardial infarction (including those
not responding to lidocaine), but it impairs cardiac contractility.
Oral administration of <span>disopyramide</span> is useful,
but it has an antimuscarinic effect which limits its use in patients
susceptible to angle-closure glaucoma or with prostatic hyperplasia.</p><p><b>Flecainide</b> belongs to the same general class as lidocaine and may be of value
for serious symptomatic ventricular arrhythmias. It may also be indicated
for junctional re-entry tachycardias and for paroxysmal atrial fibrillation.
However, it can precipitate serious arrhythmias in a
small minority of patients (including those with otherwise normal
hearts). </p><p><b>Propafenone</b> is used for the prophylaxis and treatment of ventricular arrhythmias
and also for some supraventricular arrhythmias. It has complex mechanisms
of action, including weak beta-blocking activity (therefore caution
is needed in obstructive airways disease—contra-indicated if severe). </p><p>Drugs for supraventricular arrhythmias include <b>adenosine</b>, <b>cardiac glycosides</b>, and <b>verapamil</b>; see above under <a title="BNF:monograph-family: Supraventricular arrhythmias" href="2411.htm#_2411">Supraventricular Arrhythmias</a>. Drugs for ventricular arrhythmias include <b>lidocaine</b>; see under <a title="monograph-family: Ventricular arrhythmias" href="2437.htm#_2437">Ventricular Arrhythmias</a>.</p><p>Mexiletine and procainamide are both available from <a title="appendix: Special-order Manufacturers" href="106216.htm#_106216">‘special-order’ manufacturers or specialist importing
companies</a>. Mexiletine can be used for
life-threatening ventricular arrhythmias; procainamide is given by
intravenous injection to control ventricular arrhythmias.</p></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_2417"><a href="2417.htm" title="AMIODARONE HYDROCHLORIDE">AMIODARONE HYDROCHLORIDE</a></li><li id="_2420"><a href="2420.htm" title="DISOPYRAMIDE">DISOPYRAMIDE</a></li><li id="_2426"><a href="2426.htm" title="FLECAINIDE ACETATE">FLECAINIDE ACETATE</a></li><li id="_2451"><a href="2451.htm" title="PROPAFENONE HYDROCHLORIDE">PROPAFENONE HYDROCHLORIDE</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="206568.htm">Previous: DRONEDARONE</a> | <a class="top" href="2416.htm#">Top</a> | <a accesskey="]" href="2417.htm">Next: AMIODARONE HYDROCHLORIDE</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>